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Abstract: Tamoxifen has been shown to reduce the risk of developing estrogen receptor 
(ER)-positive breast cancer by at least 50%, in both pre- and postmenopausal women. The cur-
rent challenge is to find new agents with fewer side effects and to find agents that are specifically 
suitable for premenopausal women with ER-negative breast cancer. Other selective estrogen 
receptor modulators (SERMs), such as raloxifene, arzoxifene, and lasofoxifene, have been shown 
to reduce the incidence of breast cancer by 50%–80%. SERMs are interesting agents for the 
prevention of breast cancer, but longer follow-up is needed for some of them for a complete 
risk–benefit profile of these drugs. Aromatase inhibitors have emerged as new drugs in the 
prevention setting for postmenopausal women. In the Mammary Prevention 3 (MAP3) trial, a 
65% reduction in invasive breast cancer with exemestane was observed, and the Breast Cancer 
Intervention Study-II trial, which compared anastrozole with placebo, reported a 60% reduction 
in those cancers. Although SERMs and aromatase inhibitors have been proven to be excellent 
agents in the preventive setting specifically for postmenopausal women and ER-positive breast 
cancer, newer agents have to be found specifically for ER-negative breast cancers, which mostly 
occur in premenopausal women.
Keywords: breast cancer, preventive therapy, selective estrogen receptor modulators,  aromatase 
inhibitors, high-risk women
Introduction
Breast cancer is by far the most common cancer in women worldwide, with an esti-
mated 1.67 million new cancers diagnosed in 2012.1 Breast cancer is associated with 
a variety of lifestyle choices, such as obesity, later onset of first childbirth, and the use 
of hormone replacement therapy, which is also increasing in the developing world. 
Breast cancer still remains the second cause of cancer death in the developed world. 
There has been a trend toward reduction of breast cancer mortality, due to advanced 
early detection and better therapeutic strategies. However, breast cancer incidence 
and mortality have remained extremely high.
The identification of women who are at high risk of developing the disease, which 
typically means a 5-year breast cancer risk of 1.67% or higher, is key to chemopreven-
tion of breast cancer. Traditionally, women are categorized as being high risk for breast 
cancer due to their family history. However, new developments in the ability to predict 
and modify breast cancer risk have been found. One example is mammographic density, 
which in terms of population attributable risk, accounts for more breast cancers than 
family history.2 Targeting women at high risk of developing breast cancer identified by 
biomarkers, such as breast density, atypical hyperplasia, or lobular carcinoma in situ, 
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with a high population attributable risk,3 and offering them 
agents that reduce their risk of developing the disease are 
likely to lead the way in developing this approach to cancer 
prevention.
Chemoprevention is the use of drugs, vitamins, food 
supplements, vaccines, or other agents to try to reduce the 
risk, delay the development, or recurrence of cancer, and it 
is a promising strategy for cancer prevention.4 It is therefore 
crucial to identify as precisely as possible which types of 
breast cancers can be prevented by specific agents.
Here, a comprehensive review of breast cancer pre-
vention approaches for women at high risk of developing 
the disease will be presented. Most will be dedicated to 
the discussion of selective estrogen receptor modulators 
(SERMs), of which tamoxifen is the most widely studied 
and has been used in the past few decades to treat breast 
cancer; and it has also been shown to reduce the incidence 
of invasive breast cancer. Furthermore, results have been 
reported on aromatase inhibitors (AIs) for breast cancer 
prevention in women at high risk of the disease, which will 
also be discussed in this overview.
Selective estrogen receptor 
modulators
SERMs are chemically diverse compounds with the capa-
bility to bind to estrogen receptors (ERs). They have both 
selective agonist and antagonist abilities on a variety of 
organs, which contain ERs.
Tamoxifen
Tamoxifen is a well-known and extensively researched com-
pound. Tamoxifen has been adapted for application in both 
the treatment and prevention of breast cancer.5,6 Four major 
prevention trials7–15 have been completed and published 
updated results on the use of tamoxifen as a preventive 
agent (Table 1). Overall, a reduction of 38% in the risk of 
breast cancer has been observed.6 Although no effect on 
breast cancers with ER-negative origin has been observed, 
the results from an overview of all the trials suggest that 
50% of ER-positive breast cancers can be prevented with 
5 years of active tamoxifen use. The updated results from the 
SERM overview have reported that an extended beneficial 
effect of tamoxifen is observed even after 5 years of treat-
ment completion.16
Although tamoxifen has been proven to significantly 
reduce the incidence of breast cancer, increases in endome-
trial cancer and venous thromboembolic events are the most 
serious adverse events of this drug. Overall, both adverse 
events were increased between 2 and 2.5 fold in tamoxifen 
users, but analysis of long-term follow-up data has shown that 
thromboembolic events were not in excess after tamoxifen 
treatment was stopped.10 In summary, tamoxifen prevents 
ER-positive breast cancer during the first 5 years of treat-
ment and also after treatment cessation. The benefits could 
persist even longer, and therefore tamoxifen is an attractive 
chemopreventive option, specifically in premenopausal 
women, where life expectancy is long.
Raloxifene
Raloxifene is also a SERM developed for the prevention 
of osteoporosis in postmenopausal women. Like tamox-
ifen, it has both estrogen-agonistic effects on the bone and 
lipid metabolisms and estrogen-antagonistic effects on the 
endometrial and breast tissues. All the studies investigating 
raloxifene as a preventive agent for the reduction in breast 
cancer incidence were initially developed as osteoporosis or 
cardiovascular prevention trials, and breast cancer incidence 
was a secondary endpoint.
Four trials have reported their results using raloxifene as 
a preventive agent (Table 1). Both the Multiple Outcomes 
of Raloxifene Evaluation17 and the Continuing Outcomes 
Relevant to Evista18 reported a significant reduction (65% and 
50%, respectively) in breast cancer overall. Like tamoxifen, 
an increase in thromboembolic events has been observed with 
raloxifene, but no significant excess in endometrial cancers 
or other gynecological problems has been found.
Another study was the Raloxifene Use for The Heart 
study,19 where an overall reduction of 44% for invasive breast 
cancer was found with raloxifene, which is similar in size to 
that seen for tamoxifen in other studies. A direct comparison 
between tamoxifen and raloxifene was performed in the 
Study of Tamoxifen and Raloxifene trial.20 The efficacy was 
about 25% lower for raloxifene compared with tamoxifen, but 
there were fewer thromboembolic events and gynecological 
problems with raloxifene. Although raloxifene is widely used 
in the prevention of osteoporosis, its use in the preventive 
setting for breast cancer is not common.
Other SeRMs
Two other SERMs (lasofoxifene and arzoxifene) have 
been investigated in postmenopausal women. The PEARL 
(Postmenopausal Evaluation and Risk Reduction With 
Lasofoxifene) trial recruited 8,556 postmenopausal healthy 
women to three treatment arms: placebo versus 0.25 mg/day 
lasofoxifene versus 0.5 mg/day lasofoxifene for 5 years in a 
1:1:1 ratio (Table 1).21
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All breast cancers (including ductal carcinoma in situ 
[DCIS]) were significantly reduced by 0.5 mg/day lasofox-
ifene when compared to placebo, whereas no significant 
effect was seen for women receiving 0.25 mg/day lasofox-
ifene, although a beneficial trend was seen. An even greater 
reduction was seen for invasive ER-positive breast cancer 
with 0.5 mg/day lasofoxifene. Furthermore, lasofoxifene 
significantly reduced major coronary events, strokes, and 
both vertebral and non-vertebral fractures, so may be ideal for 
prevention where the total benefit/harm balance is particularly 
important. Overall, there were no differences between the 
groups in terms of other serious adverse events.
The GENERATIONS trial evaluated the effect of arzox-
ifene (20 mg/day) versus placebo in 9,354 postmenopausal 
women with osteoporosis (Table 1).22 Arzoxifene reduced all 
breast cancer occurrences by 58%. The incidence of DCIS 
was substantially but nonsignificantly reduced. Arzoxifene 
also reduced vertebral fractures by 41% but an increase was 
seen for thromboembolic events, hot flushes, muscle cramps, 
and gynecological events.
A recently published SERM overview16 is the only com-
prehensive analysis of all SERM prevention trials to date. The 
meta-analysis reported on a substantial update on all SERM 
trials with long-term follow-up (except for the arzoxifene 
and lasofoxifene trials) and the results clearly showed that 
all SERMs significantly reduce the incidence on invasive 
ER-positive breast cancer (Figure 1). However, as seen in all 
individual trials as well, no effect of SERMs was seen for ER-
negative breast cancers, and it is clear that new approaches 
have to be found to reduce the incidence of these cancers in 
a high-risk population. Another important finding was that 
benefits from SERMs were not only seen during the active 
5 years of follow-up but also after treatment was completed, 
indicating a long-term effect of SERMs in the prevention of 
Table 1 Details of breast cancer prevention trials
N Recruitment 
period
Treatment groups and 
daily dose
Treatment 
duration 
(years)
Entry criteria Present status Median  
follow-up 
(months)
Marsden7,8 2,471 1986–96 Placebo (1,233) 
Tamoxifen 20 mg (1,238)
5–8 High risk, family 
history
Blinded, further 
follow-up
171.6 (153.9–184.0)
iBiS-i9,10 7,109 1992–2001 Placebo (3,566) 
Tamoxifen 20 mg (3,573)
5 .2-fold relative risk Blinded, further 
follow-up
96 (80.1–117.1)
NSABP-P113,14 13,205 1992–97 Placebo (6,707) 
Tamoxifen 20 mg (6,681)
5 .1.6% 5-year risk Unblinded, no 
follow-up
57.6 (35.4–64.9)
italian11,12,15 5,048 1992–97 Placebo (2,708) 
Tamoxifen 20 mg (2,700)
5 Normal risk, women 
with  
hysterectomy
Unblinded,  
further  
follow-up
139.6 (122.0–146.1)
MORe17/CORe18 7,705/6,511 1994-98/1998-
2002
Placebo (2,576)  
Raloxifene 60 mg (2,557)/
Placebo (2,576)  
Raloxifene 120 mg (2,572)
4/8 Normal risk, 
postmenopausal  
women with 
osteoporosis
Unblinded, no 
follow-up
71.3 (47.1–95.4)
RUTH19 10,101 1998–2000 Placebo (5,057) 
Raloxifene 60 mg (5,044)
5 Normal risk, 
postmenopausal  
women with 
established or  
risk of CHD
Unblinded, no 
follow-up
66.7 (60.1–72.3)
STAR20 19,490 1999–2004 Raloxifene 60 mg (9,875) 
Tamoxifen 20 mg (9,872)
5 .1.6% 5-year risk,  
postmenopausal 
women
Unblinded, no 
follow-up
81 (60.8–96.6)  
PeARL21 8,856 2001–07 Placebo (2,852) 
Lasofoxifene 0.50 mg (2,852) 
Lasofoxifene 0.25 mg (2,852)
5 Normal risk, 
postmenopausal  
women with 
osteoporosis
Blinded, no  
follow-up
59.6 (58.8–60.1)  
GeNeRATiONS22 9,354 2004–09 Placebo (4,678) 
Arzoxifene 20 mg (4,676)
4 Normal risk, 
postmenopausal  
with low BMD or 
osteoporosis
Unblinded, no 
follow-up
54.3 (28.3–56.1)
Note: Trials are sorted according to agent and recruitment period. Reprinted with permission from elsevier (The Lancet, 2013;381:1827–1834, Cuzick J, Sestak i, Bonanni B, 
et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data).16
Abbreviations: iBiS, international Breast cancer intervention Study; MORe, Multiple Outcomes of Raloxifene evaluation; CORe, Continuing Outcomes Relevant to evista; 
RUTH, Raloxifene Use for The Heart; STAR, Study of Tamoxifen And Raloxifene; CHD, coronary heart disease; BMD, bone mineral density; PeARL, Postmenopausal 
evaluation and Risk Reduction with Lasofoxifene; FU, follow-up.
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breast cancer. The decision to use a SERM for breast cancer 
prevention should not solely be based on the effect on breast 
cancer incidence. Adverse effects, notably thromboembolic 
events and, for tamoxifen only, endometrial cancers, have 
to be taken into account when assessing the risk–benefit 
ratio for each individual patient. This decision making is a 
very complex, individual, and complicated matter, but an 
improved risk–benefit ratio for SERMs might be indicated 
for women who are at high risk of breast cancer at any age 
compared to those with average risk. However, currently, the 
only chemopreventive option for premenopausal women is 
tamoxifen. Recently, in the UK, the National Institute for 
Health and Care Excellence has published updated guidelines 
for the use of tamoxifen (and raloxifene) for women at high 
risk of developing breast cancer, although these drugs are 
not licensed for this purpose in the UK.23
Aromatase inhibitors
Third-generation AIs (anastrozole, letrozole, and exemestane) 
act via the inhibition of the cytochrome P450 enzyme aro-
matase, which converts androgens into estrogens.24 In meta-
static disease, many trials have shown that AIs have great 
benefits when compared to megestrol acetate. Most of the use 
of AIs in the preventive setting derives from adjuvant studies 
in postmenopausal women with early breast cancer.
Adjuvant trials
The use of AIs has been widely investigated in postmenopausal 
women with early breast cancer (Table 1).25–30 Several differ-
ent study designs have been investigated, and most trials used 
the AI as an initial treatment,27 some used it after 2–3 years 
of tamoxifen,26,28,30 or as an extended treatment after 5 years 
of tamoxifen use.29,31 All these trials, irrespective of the study 
design, have shown a consistent reduction in contralateral 
breast cancer. Specifically, the Anastrozole, Tamoxifen, Alone 
or in Combination trial showed that 5 years of anastrozole use 
significantly improved disease-free survival when compared to 
tamoxifen,25,32–34 and the updated results confirmed the better 
efficacy of anastrozole over tamoxifen as initial adjuvant treat-
ment in postmenopausal women with early breast cancer.33
Based on these findings, AIs are being routinely used in the 
treatment of breast cancer. Furthermore, a recently conducted 
meta-analysis of adjuvant trials with AIs indicated that these 
agents consistently showed lower recurrence rates when com-
pared to tamoxifen, either as initial therapy or after 2–3 years of 
tamoxifen use.35 This overview provides clear evidence that AIs 
achieve significant reductions in breast cancer recurrence.
Prevention trials
The use of AIs in the preventive setting has not yet been 
extensively investigated. Two main prevention trials have 
Generations
Combined
0–1 0–2 0–5 0–1 0–2 0–5 0–5 0–1 0–2 0–5 1 2 5 1011 12 2 5
**
Hazard ratio P=0.002 Hazard ratio P<0.001 Hazard ratio P=0.9 Hazard ratio P=0.09
Arzofoxifene trial
Pearl 0–5 mg
Pearl 0–25 mg
Lasofoxifene trial
Star*
Ruth
More/core
Raloxifene trials
Italian
NSABP-P1
IBIS-I
Marsden
Tamoxifen trials
All breast cancer ER-positive invasive breast cancer ER-negative invasive breast cancer DCIS
Figure 1 Forest plots for all breast cancer, eR+/eR– invasive breast cancer, and DCiS according to SeRM and trial.
Notes: *Adjusted by overall tamoxifen effect to give raloxifene vs placebo comparison, STAR data not included in overall effect; **pooled data. Reprinted with permission 
from elsevier (The Lancet, 2013;381:1827–1834, Cuzick J, Sestak i, Bonanni B, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated 
meta-analysis of individual participant data).16
Abbreviations: eR, estrogen receptor; iBiS, international Breast cancer intervention Study; MORe, Multiple Outcomes of Raloxifene evaluation; CORe, Continuing 
Outcomes Relevant to evista; RUTH, Raloxifene Use for The Heart; STAR, Study of Tamoxifen And Raloxifene; eR, estrogen receptor; SeRM, selective estrogen receptor 
modulator; DCiS, ductal carcinoma in situ; PeARL, Postmenopausal evaluation and Risk Reduction with Lasofoxifene.
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reported their results to date. The Mammary Prevention 3 
(MAP3) trial compared the steroidal AI exemestane with 
placebo in postmenopausal women at increased risk of breast 
cancer, whereas the International Breast cancer Intervention 
Study-II (IBIS-II) trial investigated the use of anastrozole in 
a similar population.
The MAP3 trial enrolled over 4,500 postmenopausal 
women who were at risk of developing breast cancer and ran-
domized them to either exemestane or placebo for 5 years. After 
a median of 35 months of follow-up, 11 invasive breast cancers 
were found with exemestane versus 32 with placebo, resulting 
in a 65% reduction of invasive breast cancers with exemestane.36 
No effect was seen for ER-negative disease. No statistically 
significant differences were found between treatment arms for 
adverse events, suggesting a good risk–benefit profile. How-
ever, this trial had some limitations, most importantly the short 
follow-up period of only 35 months. Due to this immaturity, the 
MAP3 trial does not allow for any conclusion of the safety and 
long-term efficacy of this drug. Furthermore, after publications 
of the results, women on placebo were offered the opportunity 
to cross-over to exemestane, which does not permit the assess-
ment of long-term efficacy of this drug, including overall, and 
specifically, breast cancer mortality.
The IBIS-II trial compares anastrozole with placebo in 
postmenopausal women at increased risk of breast cancer. 
The main results were recently reported after a median of 
5 years of follow-up,37 and a highly significant reduction of 
invasive ER-positive breast cancers was seen with anastrozole 
compared with placebo in this high-risk population (58%, HR 
=0.42 [0.25–0.71]), which was similar to the results reported 
in the MAP3 trial. As in the MAP3 trial, no effect of anas-
trozole was found for ER-negative breast cancer. Vasomotor 
and musculoskeletal side effects were increased with the use 
of anastrozole, and these side effects were also reported by 
many women on placebo. Strengths of the IBIS-II trial were 
the large number of breast cancers reported and the median 
follow-up of 5 years. All women remain blinded for long-term 
follow-up, which is important since overall long-term efficacy 
of anastrozole, or any other AI, for healthy postmenopausal 
women at increased risk of breast cancer has not yet been 
established.
Overall, the reported reductions for both exemestane 
and anastrozole were larger than those seen for tamoxifen 
or any other SERMs, and these results indicate that both 
drugs are attractive options for breast cancer prevention in 
postmenopausal women at increased risk of the disease. For 
premenopausal women, the only option remains tamoxifen. 
Tamoxifen, exemestane, and anastrozole are all out of patent, 
and registering these drugs for use in the preventive setting 
will most probably not be marketed. Although approved by 
several regulatory authorities for the use in the preventive 
setting, these drugs, despite their effectiveness, are unfortu-
nately not widely accepted as breast cancer preventive drugs 
by high-risk women and their physicians. Reasons for the 
low uptake of chemopreventive agents, SERMs or AIs, are 
fear of side effects, general practitioners not being aware of 
chemopreventive options for high-risk women, and the drug 
industry not promoting the drugs for primary prevention.
Other agents
Other agents have emerged, although initially developed 
for other diseases, which might be useful for the prevention 
of breast cancer in high-risk women. New generations of 
chemopreventive agents that do not modulate the endocrine 
pathways have been studied recently.
Metformin
Metformin is a safe drug widely used by millions of people 
for the treatment of non-insulin-dependent diabetes. It works 
by targeting the enzyme AMP-activated protein kinase, which 
induces muscles to take up glucose from the blood. The 
rationale for the use of metformin in breast cancer preven-
tion comes from obesity being an independent risk factor for 
breast cancer in postmenopausal women. Many studies have 
shown that long-term use of metformin may have a benefi-
cial effect on breast cancer risk. Small biomarker studies in 
women with breast cancer in a placebo-controlled setting are 
ongoing and these results may lead to larger chemoprevention 
trials with metformin.
Bisphosphonates
Bisphosphonates were originally developed for the treat-
ment of osteoporosis and are commonly used in the breast 
cancer setting in controlling bone loss induced by AIs and 
chemotherapy. In addition, adjuvant breast cancer trials 
evaluating the oral bisphosphonate clodronate suggested a 
reduction in cancer recurrence, but the findings were mixed.38 
Several studies have now shown that bisphosphonates reduce 
breast cancer in postmenopausal women by around 30%.38,39 
These findings require a cautious interpretation since bis-
phosphonates are given to women with a low bone mineral 
density and these women are at a decreased risk of breast 
cancer. However, these agents are well tolerated, and primary 
prevention trials are needed to fully investigate the risk–
benefit ratio of these agents for breast cancer prevention. It is 
not clear if they are suitable for premenopausal women.
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Nonsteroidal anti-inflammatory drugs
Long-term follow-up of randomized trials using aspirin in the 
prevention of vascular disease showed that daily use reduced 
the incidence of colorectal cancer and several other cancers. 
Evidence from case–control and cohort studies indicates a 
reduction of breast cancer risk by about 10% for aspirin and 
possibly a little more for ibuprofen.40,41 Similar results have 
been found with other nonsteroidal anti-inflammatory drugs 
(NSAIDs) and COX-2 inhibitors.42 Although an effect of 
NSAIDs on breast cancer risk reduction is too small to make a 
conclusive decision regarding its sole use in the prevention of 
breast cancer, these drugs may be part of a broad intervention 
approach, specifically since a beneficial effect is seen on 
colorectal cancers and cardiovascular disease.43
The IBIS-III trial will integrate several chemopreventive 
agents in one trial. This trial will directly address the issue 
of late recurrence in postmenopausal breast cancer survivors 
and will include integrated biological studies to explore 
mechanisms of drug action and to identify which patients are 
at greatest risk of late recurrence. Specifically, this trial will 
attempt to determine which cancers are most susceptible to 
control with metformin and/or an AI and/or a bisphosphonate 
in a 2×2×2 factorial trial. Of particular interest will be any 
possible positive synergism between these agents.
Conclusion
The prevention of ER-positive breast cancer with SERMs 
is well established, and they are the only option for pre-
menopausal women to date. However, despite their efficacy, 
these drugs have not been well accepted as preventive 
agents by high-risk women or clinicians, mostly because 
of adverse events. For postmenopausal women, the AIs 
have been established for the treatment of breast cancer 
and recent publications also favor those drugs over SERMs 
in the preventive setting. Both the MAP3 and IBIS-II 
trials have reported a significant reduction for invasive 
breast cancer in postmenopausal women in the preventive 
setting.
Biomarkers are important for the identif ication of 
women at high risk, and breast density is currently the most 
attractive measure. Breast density is a well-established risk 
factor for breast cancer and it has been shown that change 
in breast density might predict drug effectiveness and 
therefore be a useful surrogate marker.44 Similarly, a recent 
publication has reported that mammographic density during 
the use of adjuvant endocrine treatment was a significant 
predictor for recurrence in women with ER-positive breast 
cancer.45
The prevention of incidence or recurrence of ER-negative 
disease remains a huge challenge, and other agents have to be 
developed for the prevention of these tumors. Recent research 
interests have been in so-called non-endocrine-based path-
ways, such as epidermal growth factor 1 or human epidermal 
growth factor. NSAIDs,46 COX-2 inhibitors,47,48 retinoids, 
rexinoids, and statins49,50 may also protect against both recep-
tor positive and receptor negative tumors, but results only 
from observational studies or adjuvant studies are available 
at the moment, and there are still inconsistencies. A new 
agent, deguelin, which prevents mammary tumorigenesis, has 
shown important advances in the prevention of ER-negative 
breast cancer.51
Of great interest are the single nucleotide polymorphisms 
(SNIPs) that individually have minor effects of risk but are 
common. Some women will have several of these SNIPs 
to have an impact on their breast cancer risk, especially in 
combination with mammographic density and other known 
factors. An assessment of how SNIPs might improve risk 
assessment among high-risk women is needed for better 
targeting of preventive therapy. In a recent study, Cuzick 
et al evaluated a panel of 15 SNIPs and found that they are 
useful for refining risk estimates in women at high risk of 
developing breast cancer.52
In conclusion, there are many options for the prevention 
of ER-positive breast cancer, specifically in postmenopausal 
women who can be given a SERM or an AI. For premeno-
pausal women, only tamoxifen can be potentially used as 
a preventive agent as AIs are not indicated in this group of 
women. It remains unclear how to prevent the incidence of 
ER-negative breast cancer, which occurs mostly in premeno-
pausal women, and more research is needed to specifically 
target this unsolved matter.
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